Main Industry
Biotechnology
Main Product/Service
Two products have been developed by the multidisciplinary research team of Academician Alice L. Yu, Professor John Yu, and Dr. Chia-Cheng Wu:
1. FnCTP-BsAb: A broad-spectrum bispecific antibody developed by combining FnCTP with T-cell-recognizing anti-CD3, designed as a universal treatment applicable to a wide variety of cancers;
2. FnCTP-MNC-Herceptin: A prototype for a novel cancer therapy constructed by combining FnCTP with Herceptin-encapsulated MNC nanoparticles.
(The content above was translated by AI.)
1. FnCTP-BsAb: A broad-spectrum bispecific antibody developed by combining FnCTP with T-cell-recognizing anti-CD3, designed as a universal treatment applicable to a wide variety of cancers;
2. FnCTP-MNC-Herceptin: A prototype for a novel cancer therapy constructed by combining FnCTP with Herceptin-encapsulated MNC nanoparticles.
(The content above was translated by AI.)
Founded Year
2019
Unified Business No.
85017827
Status
Active
Number of Employees
0
Total Paid-in
Capital
500,595,294 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
UCT Bioscience CO., LTD. is a biomedical startup established in 2019, with its core R&D focused on novel cancer biologics. The company's core technology is a broad-spectrum cancer-targeting antibody capable of recognizing multiple types of cancer tumor cells. By integrating this with an innovative technology platform—akin to the concept of loading a warhead with gunpowder—the company develops a diverse range of novel anti-cancer biomedical drugs through various physiological response mechanisms to achieve therapeutic efficacy for multiple hematological or solid tumor indications that currently lack effective treatments. In the future, in addition to continuously advancing the clinical development of FnCTP-BsAb, UCT Bioscience CO., LTD. will further collaborate with international biopharmaceutical companies using its FnCTP platform technology to develop new products that utilize FnCTP to deliver various anti-cancer drugs.
(The content above was translated by AI.)
(The content above was translated by AI.)
